Zydus Lifesciences is a global life sciences company that makes medicines, vaccines, consumer health brands, and medical devices, serving patients in over 75 countries. It began as Cadila Healthcare and, over the past decade, deliberately shed low-return businesses and pivoted from a pure generics player into a diversified healthcare organization built on complex, hard-to-copy products. The recurring approach is to move up the value chain through in-house R&D and targeted acquisitions, entering areas with high entry barriers - specialty drugs, biosimilars, rare-disease treatments, and surgical robotics - and then scaling them with the cash flows and distribution muscle of its older businesses.
Business segments
Five engines at different stages - a US generics cash cow pivoting to specialty, a fast-growing Indian branded-prescription franchise, a consumer wellness platform at national scale, a newly acquired medical-devices bet, and an innovation pipeline feeding them all - each built on the capabilities of the one before.
1. US formulations: the cash engine, now pivoting to specialty and rare disease
A top-three US generics prescription player uses its scale and customer relationships to fund a deliberate shift into higher-value specialty brands, biosimilars, and ultra-rare disease therapies.
- Volume generics provide the base - the company is ranked 5th among US generic companies by prescriptions, distributes over 225 products, and holds a top-three position in more than 55% of its product families, giving it steady demand and strong relationships with distributors.
- Specialty brands built through a faster regulatory path - it has launched three 505(b)(2) brands (Zituvio, Zituvimet, Zituvimet XR) for metabolic disorders, all approved on the first cycle, and filed two more dossiers in April 2026, using a route that is quicker than a full new-drug application because it relies partly on existing data.
- Oncology supportive care bought, not just built - the acquisition of Assertio Holdings in June 2026 delivered ROLVEDON, an approved long-acting biologic that prevents infections during chemotherapy, along with 170-plus community oncology accounts and a buy-and-bill infrastructure that lets Zydus sell directly to clinics.
- Biosimilars open the next frontier - it has in-licensed a biosimilar of Keytruda (Pembrolizumab), the world’s largest oncology drug, and an interchangeable biosimilar of Lucentis (Ranibizumab) that already has USFDA approval, giving it a path into the U.S. biologics market.
2. India branded formulations: the chronic-care powerhouse
A prescription-driven business that consistently outgrows the Indian pharma market by focusing on chronic diseases, launching first-in-country biologics, and holding the number-one position in oncology.
- Chronic therapies are the growth engine - chronic medicines now make up 46.3% of the portfolio, up more than six percentage points in three years, with cardio-diabetes, respiratory, and oncology as the largest contributors, which means more recurring prescriptions and less dependence on seasonal illness.
- First-in-market innovation creates pricing power - it launched the world’s first biosimilar of Nivolumab (an immunotherapy) at roughly one-fourth the cost of the original, India’s first indigenously developed biosimilar of Aflibercept for eye care, and a semaglutide injection for diabetes and weight management in a reusable pen, each addressing large, underserved patient pools.
- A deep bench of large brands - the portfolio includes 10 brands each worth over Rs. 1,000 million, 24 brands between Rs. 500-1,000 million, and 7 brands among India’s top 300, spread across mass-market and specialty therapy areas.
- A field force that reaches the doctor - around 5,800 medical representatives organized into mass clusters (anti-infectives, pain, GI) and specialty clusters (cardiac, oncology, nephrology, and others) call on physicians across the country, backed by a pan-India distribution network.
3. Consumer wellness: the everyday-health platform
A branded FMCG business with number-one market shares in multiple categories, now expanding into nutrition and international markets through acquisitions.
- Category leadership in everyday staples - brands like Glucon-D (58.9% share), Sugar Free (96.1% share), Complan (48.6% share), and Nutralite Fat Spread (75.5% share) hold dominant positions, giving the business pricing power and shelf space in over 2.8 million retail outlets.
- Premiumization and nutrition are the growth levers - the acquisition of Naturell brought the RiteBite Max Protein brand, ranked first in protein bars, protein cookies, and chips, while the international VMS (vitamins, minerals, supplements) business was built through the acquisition of UK-based Comfort Click, which holds the largest online market share in Europe.
- Digital and modern trade are now direct - the company has moved from a distributor-led model to direct relationships with all modern trade and e-commerce partners, with quick commerce alone accounting for over 41% of e-commerce sales, so it captures data and margins that used to sit with middlemen.
4. Medical devices: the new-build in orthopedics and beyond
A newly established vertical anchored by the acquisition of Amplitude Surgical, a top-tier French orthopedics company, with a strategy to expand into cardiology, nephrology, and continuous glucose monitoring.
- Amplitude Surgical is the cornerstone - acquired in October 2025, it holds the number-two position in France and number-six in Europe in lower-limb orthopedics, employs 429 people, and generated nearly €111 million in revenue, giving Zydus an immediate, scaled presence in surgical technologies for hip and knee replacement.
- Robotics adds a technology moat - Amplitude received CE mark approval in November 2025 for its proprietary robotic surgical system ‘Andy’, built on its own navigation platform, which helps surgeons place implants more precisely and creates a reason for hospitals to stay within the Amplitude product ecosystem.
- Distribution is being internalized - in mid-2026, Amplitude acquired two French sales agents, eliminating ongoing commission fees and bringing commercial capabilities in-house, which improves margin control.
- Adjacent device plays are emerging - the company launched Diasens and GlucoLive, AI-powered continuous glucose monitors that stream readings to a smartphone every three minutes, and has made strategic investments in portable MRI companies Promaxo and neuro42, seeding future growth in diagnostics.
5. Innovation engine: the pipeline that feeds the businesses
A 1,500-scientist R&D organization working on new chemical entities, biosimilars, and vaccines, with several molecules in global clinical trials and a track record of first-in-market launches.
- Saroglitazar is the homegrown molecule with global ambition - originally launched in India for diabetic dyslipidemia and now also approved for MASH, it is in Phase II/III trials in the US for primary biliary cholangitis, with Orphan Drug and Fast-Track designations from the USFDA that could speed its path to market.
- A broad biosimilar portfolio with first-mover DNA - the company launched the world’s first biosimilar of adalimumab (Exemptia) and the first biosimilar of Kadcyla (Ujvira), and now has 30 biologics in its portfolio, including 8 novel biologics and 22 biosimilars either commercialized or in development.
- Vaccine manufacturing at global standards - its rabies vaccine facility, one of the largest in India, received WHO prequalification, which allows it to supply UN procurement agencies like GAVI and PAHO, opening a channel to large-volume international tenders.
Group structure and partners
Zydus operates through a network of over 50 subsidiaries and four joint ventures, with separate legal entities housing each major business line and strategic partnerships filling capability gaps.
- Businesses are ring-fenced in dedicated subsidiaries - US formulations run through Zydus Pharmaceuticals USA Inc., consumer wellness through listed subsidiary Zydus Wellness Limited, rare disease through Sentynl Therapeutics Inc., MedTech through Zydus MedTech Private Limited and its French step-down subsidiaries, and the new biologics CDMO through Zylidac Bio LLC.
- Joint ventures provide manufacturing and market access - a 50:50 JV with Takeda makes generic APIs exclusively for Takeda’s global supply chain, a 50:50 JV with Pfizer’s Hospira manufactures around 30 oncology injectables, and a 75:25 marketing JV with Bayer sells prescription products in cardiology, women’s health, and specialty therapeutics in oncology, haematology, and ophthalmology in India.
- Licensing deals bring in outside molecules - partnerships with Formycon (Pembrolizumab biosimilar), Bioeq (Ranibizumab biosimilar), Synthon (Ozanimod for multiple sclerosis), and RK Pharma (oncology supportive care injectable) give Zydus access to products it did not have to invent itself, while co-marketing agreements with Lupin and Torrent expand the reach of its semaglutide in India.
- A venture arm places small bets on future technology - Zynext Ventures has invested in intracellular drug delivery (Feldan Therapeutics), portable MRI (Promaxo, neuro42), an oral sickle-cell therapy (Illexcor), and a 5.9% stake in immuno-oncology company Agenus, each a option on a technology that could become meaningful later.